JP2014518883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518883A5 JP2014518883A5 JP2014512833A JP2014512833A JP2014518883A5 JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5 JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5
- Authority
- JP
- Japan
- Prior art keywords
- tl1a
- monoclonal antibody
- clone
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 12
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 102000043656 human TNFSF15 Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Claims (12)
- DR3とTL1Aとの間の相互作用を遮断する薬剤を含んでなる、炎症性又は自己免疫性疾病を治療するための医薬組成物。
- 前記DR3とTL1Aとの間の相互作用が、DR3および/またはTL1Aの内因性レベルを減少させることによって遮断される、請求項1に記載の組成物。
- 前記薬剤が、DR3 Fc融合タンパク質、抗DR3抗体、抗TL1A抗体、およびDR3プレリガンドアセンブリードメイン(PLAD)を含んでなるペプチドから選択される1つまたはそれ以上である、請求項1に記載の組成物。
- 前記ペプチドが、配列R1−DR3 PLAD−R2 を有し、ここで、DR3 PLADは、配列番号:2のアミノ酸43−58を含んでなり、そしてここで、R1及びR2が、所望によりH、アシル、NH2、アミノ酸又はペプチドである、請求項3に記載の組成物。
- 前記炎症性又は自己免疫性疾病が、喘息、多発性硬化症、リウマチ様関節炎、炎症性腸疾患、1型糖尿病、移植片対宿主病、またはT細胞の成分による自己免疫性疾病である、請求項1に記載の組成物。
- 抗炎症剤を同定するための方法であって、前記方法の工程が、
(a)DR3及びTL1Aを含んでなる試料を用意し、
(b)試料を、候補薬剤と接触させ、
(c)DR3/TL1A結合のレベルを検出し、
(d)結合レベルを対照と比較すること
を含んでなり、対照と比較したDR3/TL1A結合における減少が抗炎症剤を同定する、前記方法。 - TL1Aに特異的に結合するモノクローナル抗体。
- ヒトTL1A及びマウスTL1Aからなる群に特異的に結合する、請求項7に記載のモノクローナル抗体。
- 前記モノクローナル抗体がヒト化されている、請求項7又は8に記載のモノクローナル抗体。
- 前記モノクローナル抗体がヒト化されており、ここで、前記抗体が、一つのアミノ酸配列を含んでなるヒト化重鎖可変領域、及び一つのアミノ酸配列を含んでなるヒト化軽鎖可変領域を含んでなる、請求項8又は9に記載のモノクローナル抗体。
- 前記抗体が、抗ヒトTL1Aクローン1A9、抗ヒトTL1Aクローン1C6、抗マウスTL1Aクローン12B12.6、または抗マウスTL1Aクローン5G4.6である、請求項7に記載のモノクローナル抗体。
- 前記抗TL1A抗体が、クローン1A9及びクローン1C6からなる群から選択される、請求項3に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161488671P | 2011-05-20 | 2011-05-20 | |
US61/488,671 | 2011-05-20 | ||
PCT/US2012/028926 WO2012161856A1 (en) | 2011-05-20 | 2012-03-13 | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014518883A JP2014518883A (ja) | 2014-08-07 |
JP2014518883A5 true JP2014518883A5 (ja) | 2015-03-19 |
Family
ID=47217582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014512833A Withdrawn JP2014518883A (ja) | 2011-05-20 | 2012-03-13 | T細胞媒介疾病の病態を改善させるためのtl1a−dr3相互作用の遮断及びその抗体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9068003B2 (ja) |
EP (1) | EP2709664A4 (ja) |
JP (1) | JP2014518883A (ja) |
KR (1) | KR20140104344A (ja) |
AU (1) | AU2012259312A1 (ja) |
CA (1) | CA2836898A1 (ja) |
MX (1) | MX2013013329A (ja) |
WO (1) | WO2012161856A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1667730B1 (en) * | 2003-08-20 | 2013-06-26 | University of Miami | Compositions and methods for treating inflammatory lung disease |
EP1919954B1 (en) | 2005-08-30 | 2016-10-19 | University of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
EP2462165B1 (en) | 2009-08-03 | 2016-05-11 | University of Miami | Method for in vivo expansion of t regulatory cells |
US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
EP2760889A4 (en) | 2011-09-30 | 2015-04-15 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES AGAINST TL1A AND USES THEREOF |
EA201591153A1 (ru) * | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
BR112015024752A2 (pt) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas |
ES2894963T3 (es) * | 2013-05-17 | 2022-02-16 | Cedars Sinai Medical Center | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn |
US20160096885A1 (en) * | 2013-05-17 | 2016-04-07 | Cedars-Sinal Medical Center | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
AU2014317991A1 (en) * | 2013-09-06 | 2016-03-10 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-TL1A therapy |
IL245001B2 (en) * | 2013-11-13 | 2023-05-01 | Pfizer | Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses |
WO2015166486A1 (en) * | 2014-04-28 | 2015-11-05 | The National Institute for Biotechnology in the Negev Ltd. | Variants of dr3 and use thereof |
JP2018523488A (ja) * | 2015-08-21 | 2018-08-23 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 自己免疫疾患の治療及び診断のために組み合わせて使用するための組成物及び方法 |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
US20180319889A1 (en) * | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
KR102464372B1 (ko) | 2016-03-17 | 2022-11-04 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
CN110121509B (zh) * | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
KR20210005169A (ko) | 2018-04-25 | 2021-01-13 | 프로메테우스 바이오사이언시즈, 인크. | 최적화된 항tl1a 항체 |
MX2022004942A (es) | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
CA3162617A1 (en) * | 2019-11-22 | 2021-05-27 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
WO2023244089A1 (ko) * | 2022-06-17 | 2023-12-21 | 주식회사 셀렉신 | 인간 dr3에 특이적으로 결합하는 항체 및 이의 용도 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
AU669367B2 (en) | 1992-04-28 | 1996-06-06 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
GB2294267B (en) | 1993-06-03 | 1996-11-20 | Therapeutic Antibodies Inc | Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies |
US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
JP2000501284A (ja) | 1995-11-14 | 2000-02-08 | ビムラックス ホールディングズ,リミテッド | Rna切断活性を有するキメラオリゴマー |
KR0161881B1 (ko) | 1995-12-05 | 1999-02-01 | 문정환 | 메모리의 데이타 읽기회로 |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
AU7976198A (en) | 1997-06-19 | 1999-01-04 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
EP1667730B1 (en) * | 2003-08-20 | 2013-06-26 | University of Miami | Compositions and methods for treating inflammatory lung disease |
WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
EP1919954B1 (en) * | 2005-08-30 | 2016-10-19 | University of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
US20110217310A1 (en) * | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
WO2009064854A2 (en) | 2007-11-13 | 2009-05-22 | Cogenesys, Inc | Humanized antibodies against tl1a |
-
2012
- 2012-03-13 MX MX2013013329A patent/MX2013013329A/es not_active Application Discontinuation
- 2012-03-13 AU AU2012259312A patent/AU2012259312A1/en not_active Abandoned
- 2012-03-13 US US13/419,203 patent/US9068003B2/en active Active
- 2012-03-13 WO PCT/US2012/028926 patent/WO2012161856A1/en active Application Filing
- 2012-03-13 JP JP2014512833A patent/JP2014518883A/ja not_active Withdrawn
- 2012-03-13 KR KR1020137033718A patent/KR20140104344A/ko not_active Application Discontinuation
- 2012-03-13 CA CA2836898A patent/CA2836898A1/en not_active Abandoned
- 2012-03-13 EP EP12790157.7A patent/EP2709664A4/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014518883A5 (ja) | ||
Müller et al. | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain | |
US11286312B2 (en) | Multispecific antibodies | |
JP2018121657A5 (ja) | ||
JP2017114866A5 (ja) | ||
JP2015214563A5 (ja) | ||
HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
US20170081404A1 (en) | New bispecific format suitable for use in high-through-put screening | |
JP2012501669A5 (ja) | ||
CN113226471A (zh) | Il-11ra抗体 | |
JP2012501670A5 (ja) | ||
RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
JP2012143232A5 (ja) | ||
JP2018516853A5 (ja) | ||
JP2020501532A5 (ja) | ||
JP2011523550A5 (ja) | ||
JP2013539369A5 (ja) | ||
JP2015212281A5 (ja) | ||
TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
RU2016123839A (ru) | Новые модуляторы и способы их применения | |
JP2012520679A5 (ja) | ||
JP2018502572A5 (ja) | ||
JP2010533498A5 (ja) | ||
JP2016531924A5 (ja) | ||
JP2012531922A5 (ja) | Toll様受容体2へのヒト化抗体またはその抗原結合部位 |